NDAORALCAPSULE
Approved
Apr 2016
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
ACTICLATE CAP (doxycycline hyclate) by Molecular Devices is 12. Approved for acne vulgaris, gonorrhea, chlamydia and 2 more indications. First approved in 2016.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACTICLATE CAP is an oral doxycycline hyclate capsule, a tetracycline-class antimicrobial that inhibits bacterial protein synthesis. It is indicated for acne vulgaris, gonorrhea, chlamydia, syphilis, and other sexually transmitted infections. The drug achieves peak plasma levels within 3 hours and maintains therapeutic concentrations over 24 hours.
Peak
Product is in peak commercial phase with moderate competitive pressure (30/100), suggesting stable but defended market position with potential for brand team growth and focused market defense initiatives.
Mechanism of Action
12.1 Mechanism of Action Doxycycline is a tetracycline-class antimicrobial drug [see ] . 12.3 Pharmacokinetics Absorption Doxycycline hyclate tablets: Following administration of a single 300 mg dose to adult volunteers, average peak plasma doxycycline levels were 3.0 mcg per mL at 3 hours,…
Worked on ACTICLATE CAP at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.